Imricor Medical Systems (ASX: IMR) is gaining commercial momentum in the United States, with September-quarter revenue climbing 437% as its innovative cardiac technology begins generating sales in the world's largest healthcare market.

With US$62.1 million in cash, its first American hospital customers and further regulatory milestones approaching, Imricor is building the foundations for broader commercial adoption. The next opportunity lies in converting these early achievements into sustained revenue growth.

Key Numbers

• US$188,000: September-quarter revenue, up 437% from US$34,791 a year earlier.
• US$62.1 million: Cash and cash equivalents at 30 September 2026.
• US$41.6 million: Net proceeds from the May 2026 equity capital raising.
• US$21.4 million: Operating cash outflow for the first nine months of 2026.
• US$212,452: Nine-month revenue, reflecting the early stage of commercial expansion.

First US Sales Mark an Important Commercial Milestone

Imricor's September-quarter results highlight meaningful progress in its transition from medical technology development to commercial deployment.

The company recorded its first US commercial revenue following the sale of a NorthStar Mapping System in September.

This follows commercial relationships with Rady Children's Hospital in San Diego and Children's Medical Center Dallas, establishing an initial foothold in the American healthcare market.

NorthStar enables cardiac procedures using magnetic resonance imaging rather than conventional X-ray guidance, potentially reducing radiation exposure while providing detailed anatomical visualisation.

For Imricor, these early hospital relationships represent more than individual equipment sales. They provide opportunities to demonstrate clinical performance, establish reference sites and support future adoption.

Although nine-month revenue declined approximately 8% to US$212,452, the substantial September-quarter increase suggests commercial activity is beginning to accelerate.

What Stands Out to Us

Imricor's competitive opportunity centres on its specialised technology, regulatory progress and collaboration with established medical imaging providers.

Its relationship with Philips, including the introduction of a commercial interventional magnetic resonance laboratory solution in August, could help expand its reach into additional hospitals.

Importantly, the business model offers potential for revenue beyond initial equipment installations through recurring consumables associated with cardiac procedures.

The company's financial position also provides flexibility to pursue expansion.

Imricor held US$62.1 million in cash at September's end, following its May capital raising.

Nine-month operating cash outflow reached US$21.4 million, reflecting continued investment in research, regulatory approvals and commercial operations.

At that historical operating cash consumption rate, available cash represents approximately 26 months of theoretical operating runway, excluding future spending changes and other financial obligations.

The company also reported US$29.1 million in related-party convertible notes classified as current liabilities, making future financing arrangements an important consideration.

With revenue still emerging, valuation depends primarily on commercial adoption, future recurring sales and the company's ability to achieve operating scale.

What the Company Is Doing Now

Imricor is advancing several initiatives designed to strengthen its commercial position.

Alongside its US hospital expansion, the company continues progressing regulatory approvals for additional cardiac ablation technology.

In October, the US Food and Drug Administration completed its review of the third module of Imricor's premarket approval application.

The review identified a software-related deficiency involving the RF-5000 System, which the company indicated it had addressed through an operating system update.

Imricor is targeting submission of its fourth module in November 2026.

Further regulatory progress could expand the range of procedures supported by its technology and strengthen its commercial offering.

Insight: Is Imricor Approaching a New Phase of Commercial Growth?

We see encouraging signs that Imricor's years of technology development are beginning to translate into commercial opportunities. Its first US sales, hospital relationships and Philips collaboration provide a credible foundation for expansion. The substantial cash balance also supports continued investment as adoption develops. While operating losses and funding obligations remain important considerations, the more significant opportunity lies in establishing recurring revenue across a growing hospital network. We think sustained customer growth, regulatory progress and higher procedure volumes could materially strengthen Imricor's long-term commercial outlook.

What Happens Next?

The coming 6–18 months could be important for Imricor as it pursues additional US hospital installations, progresses regulatory submissions and works to expand recurring product sales.

Further customer wins, increasing procedure volumes and stronger quarterly revenue would provide evidence that its commercial strategy is gaining traction.

For shareholders, Imricor's growing US presence represents an encouraging development. The next milestone will be demonstrating that early hospital adoption can evolve into a scalable, recurring revenue business with a credible path towards sustainable profitability.